Samina Khan

Nessuna posizione attualmente

Patrimonio netto: 7 M $ in data 30/09/2023

59 anni

Consumer Services

Health Technology

Profilo

Attualmente, Samina Khan ricopre la posizione di Chief Medical Officer e Senior Vice President di Reata Pharmaceuticals, Inc. La dottoressa Khan è stata in precedenza vicepresidente dei programmi cardio-renali alla Quark Pharmaceuticals, Inc.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
REATA PHARMACEUTICALS, INC. CLASS A 0.12%	16/05/2023	39 491 ( 0.12% )	7 M $	30/09/2023

Precedenti posizioni note di Samina Khan

Società	Posizione	Fine
REATA PHARMACEUTICALS, INC.	Chief Tech/Sci/R&D Officer	26/09/2023
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Corporate Officer/Principal	01/04/2017
Tufts University School of Medicine	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Samina Khan

Formazione di Samina Khan

Brandeis University	Masters Business Admin
Harvard Medical School	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Samina Khan

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Reata Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.	Health Technology
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Health Technology